Back9 Meters Biopharma Overview
9 Meters Biopharma, Inc.

9 Meters Biopharma Return on Equity

9 Meters Biopharma (NMTRQ) has a ROE of 790.59%, above the Technology sector average of 34.19%.

Get informed when a big investor buys or sells

+ Follow

ROE

790.59%

Return on Equity

790.59%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

9 Meters Biopharma (NMTRQ) FAQ

9 Meters Biopharma posts a ROE of 790.59%. That is above the Technology sector average of 34.19%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Technology stocks, a ROE near 34.19% is typical. 9 Meters Biopharma's 790.59% is higher that level. That is roughly 2212.0% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

9 Meters Biopharma's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 790.59%; use YoY and peer views to separate noise from signal.

Context for NMTRQ's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 34.19%), and (3) consistency with growth and profitability. This page covers the first two; 9 Meters Biopharma's other metric pages and overview cover the third.

Judging 9 Meters Biopharma against Technology peers is usually better than using a market-wide rule of thumb. Business models inside Technology are more comparable, which makes gaps in ROE easier to interpret. Start with 790.59% here, then scan peer and history charts to see if the gap is persistent.